Pregnancy, pre-eclampsia and disseminated intravascular coagulation.
A prospective evaluation of the haemostatic mechanism was undertaken in 15 normal primigravidas and in 12 primigravidas with mild to moderately severe pre-eclampsia in order to further examine the possibility that disseminated intravascular coagulation may occur in this clinical syndrome. The only coagulation abnormality demonstrated was a prolongation of bleeding time. The data do not support the suggestion that significant disseminated intravascular coagulation is associated with pre-eclampsia. The addition of the heparinoid drug sodium pentosan polysulphate to the therapeutic regimen resulted in a significant fall in platelet factor 3 availability and in decreased aggregation against ADP but conferred no objective clinical improvement. We conclude that the drug has no place in the management of established pre-eclampsia.
D000244:Adenosine Diphosphate; D000328:Adult; D001780:Blood Coagulation Tests; D004211:Disseminated Intravascular Coagulation / Q000150:complications*; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D010426:Pentosan Sulfuric Polyester / Q000627:therapeutic use; D010974:Platelet Aggregation; D010977:Platelet Factor 3 / Q000032:analysis; D011225:Pre-Eclampsia / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000150:complications*; D011446:Prospective Studies
D010977:Platelet Factor 3; D010426:Pentosan Sulfuric Polyester; D000244:Adenosine Diphosphate; D005337:Fibrin; D005340:Fibrinogen